Aegerion Pharma (AEGR) Surges on Japanese Approval of JUXTAPID

September 28, 2016 4:45 PM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Aegerion Pharma (NASDAQ: AEGR) is gaining 33% after-hours after the company announced that Japans Ministry of Health, Labor & Welfare (MHLW) has approved JUXTAPID for patients with homozygous familial hypercholesterolemia (HoFH).



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

FDA, Momentum Movers, Trader Talk

Add Your Comment